We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.
COVID-19 Drug Treatment , Humans , Alanine/therapeutic use , Antiviral Agents/therapeutic use , Finland/epidemiology , Hospitalization , Quality of Life , Treatment Outcome , Randomized Controlled Trials as Topic , Post-Acute COVID-19 Syndrome
ARTS will be the first trial to compare anticoagulation with a direct oral anticoagulant (apixaban) versus no anticoagulation among patients undergoing intra-abdominal, gynecologic, or urologic surgery at sufficiently similar risk of deep vein thrombosis or pulmonary embolism and major bleeding.
Anticoagulants , Pulmonary Embolism , Venous Thromboembolism , Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Female , Hemorrhage/etiology , Humans , Pulmonary Embolism/etiology , Pulmonary Embolism/prevention & control , Surgical Procedures, Operative/adverse effects , Venous Thromboembolism/etiology , Venous Thromboembolism/prevention & control